-
摘要: 原发性肾上腺淋巴瘤(primary adrenal lymphoma, PAL)临床表现不典型, 多数患者存在局部疼痛或全身发热、消瘦症状, 在双侧受累患者中肾上腺皮质功能不全很常见, 但仅少数患者进行全面系统的检查。正电子发射断层扫描/计算机体层成像是定性定位诊断这类肾上腺肿瘤的有效手段, 磁共振成像用来区别肾上腺淋巴瘤与皮质癌尚有待更多研究证实。对于PAL的治疗尚需进一步研究, 以对此类患者制定最佳的诊疗方案。目前, 尚不清楚利妥昔单克隆抗体联合CHOP方案(环磷酰胺+阿霉素+长春新碱+强的松)治疗高危侵袭性PAL患者是否可提高患者完全反应率。病变早期, 尤其是在肾上腺皮质功能不全出现之前诊断PAL, 有助于减少患者的发病率和死亡率。Abstract: The clinical presentation of primary adrenal lymphoma(PAL) is comprised of major general symptoms. Although adrenal insufficiency is very common in patients with bilateral involvement, it has not been systematically tested. Positron emission tomography is an efficient examination to visualize extra-adrenal locations. The preliminary results of magnetic resonance imaging to distinguish between PAL and adrenocortical carcinoma should be confirmed. Further studies are needed to establish an optimal strategy for the management of patients with PAL. At present, it is unclear whether the adjunction of rituximab (R) and CHOP(cyclophosphamide, doxorubicin, vincristine, prednisone) can cure patients with high-risk aggressive lymphoma. It is also unknown whether the prolonged complete response was due to R-CHOP alone. It is necessary to emphasize that early diagnosis of PAL before the appearance of adrenal insufficiency contributes to decreasing the patients' morbidity and mortality.
-
Key words:
- adrenal lymphoma /
- primary /
- diagnosis /
- chemotherapy
利益冲突 无 -
[1] Rashidi A, Fisher SI. Primary adrenal lymphoma:a systematic review[J]. Ann Hematol, 2013, 92:1583-1593. doi: 10.1007/s00277-013-1812-3 [2] Kumar R, Xiu Y, Mavi A, et al. FDG-PET imaging in primary bilateral adrenal lymphoma:a case report and review of the literature[J]. Clin Nucl Med, 2016, 30:222-230. https://www.ncbi.nlm.nih.gov/pubmed/15764875 [3] Kasaliwal R, Goroshi M, Khadilkar K, et al. Primary Adrenal Lymphoma:A Single-center Experience[J].Endocr Pract, 2015, 21:719-724. doi: 10.4158/EP14471.OR [4] Martínez-Esteve A, García-Gómez FJ, Madrigal-Toscano MD, et al. Primary bilateral diffuse large B-cell lymphoma of the adrenals[J]. Br J Haematol, 2015, 170:3. doi: 10.1111/bjh.13466 [5] Raoofziaee M, Yarmohamadi A, Ahmadnia H.Primary bilateral non-Hodgkin's lymphoma of the adrenal gland[J].Indian J Urol, 2018, 34:300-302. doi: 10.4103/iju.IJU_113_18 [6] Ohkura Y, Shindoh J, Haruta S, et al. Primary Adrenal Lymphoma Possibly Associated With Epstein-Barr Virus Reactivation Due to Immunosuppression Under Methotrexate Therapy[J]. Medicine, 2015, 94:e1270. doi: 10.1097/MD.0000000000001270 [7] Mozos A, Ye H, Chuang WY, et al. Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis[J]. Mod Pathol, 2009, 22:1210-1217. doi: 10.1038/modpathol.2009.87 [8] Grigg AP, Connors JM. Primary adrenal lymphoma[J]. Clin Lymphoma, 2016, 4:154-160. https://www.ncbi.nlm.nih.gov/pubmed/12769357 [9] Padhi S, Sahoo J. Primary adrenal non Hodgkin lymphoma:changing trends[J]. Turk J Gastroenterol, 2015, 26:85-86. doi: 10.5152/tjg.2015.4882 [10] Erçolak V, Kara O, Günaldi M, et al. Bilateral primary adrenal non-hodgkin lymphoma[J]. Turk J Haematol, 2014, 31:205-206. doi: 10.4274/tjh.2013.0195 [11] Robertus JL, Harms G, Blokzijl T, et al. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma[J]. Mod Pathol, 2009, 22:547-555. doi: 10.1038/modpathol.2009.10 [12] Nakatsuka S, Hongyo T, Syaifudin M, et al. Mutations of p53, c-kit, K-ras, and beta-catenin gene in non-Hodgkin's lymphoma of adrenal gland[J]. Jpn J Cancer Res, 2002, 93:267-274. doi: 10.1111/j.1349-7006.2002.tb02168.x [13] Ide M, Fukushima N, Hisatomi T, et al. Non-germinal cell phenotype and Bcl-2 expression in primary adrenal diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2007, 48:2244-2246. doi: 10.1080/10428190701636450 [14] Hong J, Park S, Park J, et al. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy[J]. Leuk Lymphoma, 2011, 52:1904-1912. doi: 10.3109/10428194.2011.588761 [15] Hans CP, Weisenburger DD, Greiner TC, et al. Confirma-tion of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103:275-282. doi: 10.1182/blood-2003-05-1545 [16] Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy[J]. Clin Cancer Res, 2009, 15:5494-5502. doi: 10.1158/1078-0432.CCR-09-0113 [17] Eyden B, Chakrabarty B, Hatimy U. Carcinoma versus cytokeratin-positive lymphoma:a case report emphasizing the diagnostic role of electron microscopy[J]. Ultrastruct Pathol, 2009, 33:33-38. doi: 10.1080/01913120802625830 [18] Rashidi A, Bergeron CW, Fisher SI, et al. Primary adrenal de novo CD5-positive diffuse large B-cell lymphoma[J]. Ann Hematol, 2013, 92:1281-1282. doi: 10.1007/s00277-013-1690-8 [19] Donner LR, Mott FE, Tafur I. Cytokeratin-positive, CD45-negative primary centroblastic lymphoma of the adrenal gland:a potential for a diagnostic pitfall[J]. Arch Pathol Lab Med, 2001, 125:1104-1106. https://www.ncbi.nlm.nih.gov/pubmed/11473470 [20] Chen P, Jin L, Yang Y, et al. Bilateral primary adrenal diffuse large B cell lymphoma without adrenal insufficiency:A case report and review of the literature[J]. Mol Clin Oncol, 2017, 7:145-147. doi: 10.3892/mco.2017.1264 [21] Chakrabarti I, Bhowmik S, Sinha MG, et al. Ultrasound-guided aspiration cytology of retroperitoneal masses with histopathological corroboration:A study of 71 cases[J]. J Cytol, 2014, 3115-3119. [22] Mehmood S, Jahan A, Loya A, et al. Onsite cytopathology evaluation and ancillary studies beneficial in EUS-FNA of pancreatic, mediastinal, intra-abdominal, and submucosal lesions[J]. Diagn Cytopathol, 2015, 43:278-286. doi: 10.1002/dc.23207 [23] Guo AC, Cummings TJ, Dash RC. Lymphomas and high-grade astrocytomas:comparison of water diffusibility and histologic characteristics[J]. Radiology, 2002, 224:177-183. doi: 10.1148/radiol.2241010637 [24] Kuritzkes B, Parikh M, Melamed J, et al. False-positive rate of positron emission tomography/computed tomography for presumed solitary metastatic adrenal disease in patients with known malignancy[J]. Ann Surg Oncol, 2015, 22:437-440. doi: 10.1245/s10434-014-4031-9 [25] Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diag-nostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies-a multicenter experience[J]. Hell J Nucl Med, 2015, 18:97-102. [26] López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma:clinical and biological characteriza-tion and outcome according to the nodal or extranodal primary origin[J]. J Clin Oncol, 2005, 23:2797-2804. doi: 10.1200/JCO.2005.07.155 [27] Abe R, Ogawa K, Maruyama Y, et al. Spontaneous regression of diffuse large B-cell lymphoma harbouring Epstein-Barr virus:a case report and review of the literature[J]. J Clin Exp Hematop, 2007, 47:23-26. doi: 10.3960/jslrt.47.23 [28] Marković O, Marisavljević D, Jelić S, et al. Double-hit primary unilateral adrenal lymphoma with good outcome[J]. Vojnosanit Pregl, 2014, 71:689-692. doi: 10.2298/VSP1407689M [29] Kim YR, Kim JS, Min YH, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)[J]. J Hematol Oncol, 2012, 5:49. doi: 10.1186/1756-8722-5-49 [30] Acker SN, Bruny JL, Garrington TP, et al. Minimally invasive surgical techniques are safe in the diagnosis and treatment of pediatric malignancies[J]. Surg Endosc, 2015, 29:1203-1208. doi: 10.1007/s00464-014-3795-0 [31] Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346:235-242. doi: 10.1056/NEJMoa011795 [32] Hiemcke-Jiwa LS, Leguit RJ, Radersma-van Loon JH, et al.Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement[J]. Leuk Lymphoma, 2017, 29:1-4. http://europepmc.org/abstract/MED/28849690 [33] Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)[J]. Ann Oncol, 2007, 18:149-157. doi: 10.1093/annonc/mdl327 [34] Ferreri AJ, Assanelli A, Crocchiolo R, et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas:incidence, risk factors and therapeutic options[J]. Hematol Oncol, 2016, 27:61-70. doi: 10.1002/hon.881
点击查看大图
计量
- 文章访问数: 469
- HTML全文浏览量: 35
- PDF下载量: 140
- 被引次数: 0